TriSalus Life Sciences, Inc.
TLSI Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 23, 2026
$3.59
KIRA · Stoqly’s AI analyst, in plain words
- TriSalus Life Sciences, Inc. had $45.2M of revenue in fiscal 2025, up 53.4% on the year before.
- Its operating margin was −59.7%, up 63.2 pts: of every 100 in sales, about −60 is left after running the business.
- TriSalus Life Sciences, Inc. lost $39.2M in fiscal 2025.
- Free cash flow was −$18.9M in fiscal 2025, −41.9% of revenue.
- TriSalus Life Sciences, Inc. owes $12.7M more than it holds in cash.
Market cap
$209M
P/E
—
Revenue
$45.2M
Net income
−$39.2M
Free cash flow
−$18.9M
Operating margin
−59.7%
TriSalus Life Sciences, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+53.4%
Yes. Sales grew 53.4% last year.
Does it make a profit?
−86.9%
No. It lost money last year.
Does profit turn into cash?
−41.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What TriSalus Life Sciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- TriSalus Life Sciences, Inc.
- CIK
- 0001826667
TriSalus Life Sciences, Inc. · TLSI
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $12.4M | $18.5M | $29.4M | $45.2M |
| Revenue growth | — | — | 49.3% | 59.0% | 53.4% |
| Gross margin | — | 81.8% | 85.9% | 86.1% | 84.6% |
| Operating margin | — | −293.9% | −294.3% | −122.9% | −59.7% |
| Net income | $4.8M | −$47.2M | −$59.4M | −$30.0M | −$39.2M |
| Net margin | — | −380.6% | −320.7% | −102.1% | −86.9% |
| Diluted EPS | — | −$161.55 | −$6.77 | −$1.31 | −$1.84 |
| Cash | |||||
| Cash from operations | −$1.7M | −$32.3M | −$50.6M | −$40.8M | −$18.0M |
| Capital expenditure | — | $0.7M | $0.6M | $0.3M | $0.9M |
| Free cash flow | — | −$33.0M | −$51.2M | −$41.2M | −$18.9M |
| FCF margin | — | −265.9% | −276.4% | −139.9% | −41.9% |
| Share buybacks | — | $232M | — | — | — |
| Share count change | — | — | 2,934.8% | 169.6% | 49.6% |
| Debt and strength | |||||
| Cash and short-term investments | $0.2M | $9.4M | $11.8M | $8.5M | $20.4M |
| Debt incl. finance leases | — | — | $0.2M | $22.2M | $33.1M |
| Shareholders' equity | −$130M | −$177M | −$27.1M | −$25.9M | −$33.9M |
| Current ratio | 0.3x | 0.5x | 1.4x | 2.0x | 2.8x |
| Interest coverage | — | −36,439.0x | −3,404.7x | −11.7x | −4.9x |
| Returns and quality | |||||
| Piotroski F-score | — | — | 4 | 4 | 4 |
| Altman Z'' | −8.2 | −48.7 | −46.9 | −45.8 | −32.3 |
Insiders bought, 12 months
$3.6M
6 insiders
Insiders sold, 12 months
$0.1M
5 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
TriSalus Life Sciences, Inc. · TLSI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.59 a share, the company is worth $209M.
Source: SEC EDGAR XBRL filings (CIK 0001826667). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.